



To whom it may concern:

September 21, 2021

Company	Takara Bio Inc. (First Section of the TSE, code: 4974)
Headquarters	Nojihigashi 7-4-38, Kusatsu, Shiga 525-0058, Japan
Representative	Koichi Nakao, President & CEO
Contact	Takuya Kakemi, Executive Officer, President of Corporate Management Division
Telephone	(+81)77-565-6970
Website	https://www.takara-bio.co.jp

Notice of Resolution of the Board of Directors on Selection of “Prime Market” Listing on the Tokyo Stock Exchange under the New Market Segments

Takara Bio Inc. resolved at the Board of Directors meeting held today to apply for "Prime Market" from the Tokyo Stock Exchange, Inc. (hereinafter “TSE”) for the new market segments, and submitted an application for market selection.

On July 9, 2021, we had received the notice from TSE on the results of the initial assessment of its compliance with the Listing Maintenance Criteria of the New Market Segments, and confirmed that the Company is in compliance with the listing criteria of the New Market Segments, the “Prime Market”.

Notes on handling this material

Statements made in this document with respect to our current plans, estimates, strategies, beliefs and other statements that are not historical facts are forward-looking statements about our future performance, which are based on our management's beliefs in light of information currently available, but which are based on a number of assumptions and beliefs in light of information that involves substantial risks and uncertainties. Please be aware that actual results may differ materially from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.